| Species |
Human |
| Protein Construction |
AMHRII (Pro18-Ser144)
Accession # Q16671-1 |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized AMHRII, Human at 1μg/ml (100μl/Well) on the plate can bind AntiAMHRII Antibody, hFc Tag. Test result was comparable to standard batch |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
14.3 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 30-40 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The aim of the current study was to explore whether anti-Müllerian hormone receptor II (AMHRII) genetic variants influence the hormonal profile and the ovarian response to standard gonadotropin stimulation of women undergoing medically assisted reproduction. Three hundred in vitro fertilization or intracytoplasmic sperm injection patients constituted the study population, while 300 women with at least one spontaneous pregnancy participated as controls. |
| Synonyms |
MIS type II receptor; MISRII; MRII; AMHR; MISR2; AMHR2; AMH type II receptor; AMHR2; AMHRII; C14 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
